The prospects of creating a therapeutic anti-cancer vaccine using the HPV16 E2 regulatory gene have been investigated. An expression system for the synthesis of early antigenic proteins HPV16 E2, of high-risk papillomavirus based on transgenic tomato fruits has been developed. To induce malignant transformation of tissues, female mice at an age of 6 months were injected with a suspension of HeLa cancer cells into the hip muscle. In 1 month, blood was collected from half of the mice, splenocytes were isolated from the spleen, and alterations in internal organs, including the lungs, were studied. The other half of the HeLa-injected mice received a peroral inoculation with vaccine material from tomatoes with HPV16 E2 (500 mg of E2 protein per mouse). In 1 month, blood was collected from the vaccinated mice, splenocytes were isolated, and alterations in internal organs were investigated. After the injection of HeLa tumor cells, the lungs increased in size and contained various tumors. The mice with HeLa administration and the peroral HPV16 E2 vaccination had no specific abnormalities in the size and morphology of the lungs. Comparing the levels of interferon, CD4 and CD8 T lymphocytes, as well as the cells that interacted with anti-granzyme B and anti-perforin antibodies, showed that HPV16 E2 vaccination increased the number of cells that bind antibodies to interferon, CD4 and CD8 T lymphocytes, granzyme B, and perforin by 1.5–2 orders of magnitude. The HPV16 E2 protein can significantly suppress the proliferation of cancer cells and can be used for the creation of a therapeutic vaccine against a cancer caused by the most highly oncogenic type of papillomavirus, HPV16.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
S. Syrjanen, Eur. J. Oral Sci. 126, 49 (2018). https://doi.org/10.1111/eos.12538
M. Upadhyay and P. Vivekanandon, Plos One 10 (11), e0142368 (2015). https://doi.org/10.1371/journal.pone.0142368
K. van Doorslaer, V. Ruoppolo, A. Schmidt, et al., Virus Evolution 3 (2), vex027 (2017). https://doi.org/10.1093/ve/vex027
S. Menon, A. Wusiman, M. C. Boily, et al., Plos One 11 (10), e0163965 (2016). https://doi.org/10.1371/journal.pone.0163965
N. Egawa and J. Doorbar, Virus Res. 231, 119 (2017). https://doi.org/10.1016/j.virusres. 2016.12.017
N. N. Venkatesan, H. S. Pine, and M. P. Underbrink, Otolaryngol. Clin. North Am. 45, 671-ix (2012). https://doi.org/10.1016/j.otc.2012.03.006
R. Y. Seedat, Pediatr. Health, Med. Ther. 11, 39 (2020). https://doi.org/10.2147/PHMT.S200186
A. Touze, S. de Sanjose, P. Coursaget, et al., J. Clin. Microbiol. 39, 4344 (2001). https://doi.org/10.1128/jcm.39.12.4344-4348.2001
F. X. Bosch, T. R. Broker, D. Forman, et al., Vaccine 31, I1-31 (2013). https://doi.org/10.1916/j.vaccine.2013.07026
J. Ferlay, F. Bray, P. Pisany, et al., GLOBOCAN 2002: Cancer Incidence, Mortality, and Prevalence Worldwide, Version 2.0, IARC CancerBase No. 5 (Int. Agency Res. Cancer, Lyon, France, 2004).
L. E. Markowitz, E. F. Dunne, M. Saraiya, et al., Morbid. Mortal. Weekly Rep. Recomm. Rep. 63, 1 (2014).
S. Taylor, E. Bunge, M. Bakker, and X. Castellsague, BMC Infectious Diseases 16, 293 (2016). https://doi.org/10.1186/S12879-016-1633-9
M. Dadar, S. Chakraborty, K. Dhama, et al., Front. Immunol. 9, 2478 (2018). https://doi.org/10.3389/fimmu.2018.02478
A. Yang, J. Jeang, K. Cheng, et al., Expert Rev. Vaccines 15, 989 (2016). https://doi.org/10.1586/14760584.2016.1157477
R. K. Salyaev, N. I. Rekoslavskaya, A. S. Stolbikov, and A. V. Tretyakova, Dokl. Biochem. Biophys. 474, 186 (2017). https://doi.org/10.1134/S1607672917030140
J. Mold, P. Reu, A. Olin, et al., PLOS Biol. 17, e3000383 (2019). https://doi.org/10.1371/journal.pbio.3000383
H. J. McFarl, J. D. Berkson, and J. P. Lee, et al., Vaccine 33, 3865 (2015). https://doi.org/10.1016/j.vaccine.2015.06.070
L. Muller, P. Aigner, and D. Stoiber, Front. Immunol. 8, 304 (2017). https://doi.org/10.3389/fimmu.2017.00304
R. K. Salyaev, N. I. Rekoslavskaya, and A. S. Stolbikov, Dokl. Biochem. Biophys. 488, 316 (2019). https://doi.org/10.1134/S1607672919050077
W. M. Schneider, M. D. Chevillotte, and C. M. Rice, Ann. Rev. Immunol. 32, 513 (2014). https://doi.org/10.1146/annurev-immunol-032713-120231
M. de Smet, S. Kanginakudru, A. Rietz, et al., PLOS Pathogens. 12, e1005934 (2016). https://doi.org/10.1371/journal.ppat.1005934
W. Alazawi, M. Pett, S. Strauss, et al., Brit. J. Cancer 91, 2063 (2004). https://doi.org/10.1038/sj.bjc.6602237
R. K. Salyaev, N. I. Rekoslavskaya, and A. S. Stolbikov, Dokl. Biochem. Biophys. 488, 296 (2019). https://doi.org/10.1134/S1607672919050028
R. K. Salyaev, N. I. Rekoslavskaya, and A. S. Stolbikov, Dokl. Biochem. Biophys. 482, 271 (2018). https://doi.org/10.1134/S1607672918050113
R. K. Salyaev, N. I. Rekoslavskaya, and A. S. Stolbikov, Dokl. Biochem. Biophys. 484, 52 (2019). https://doi.org/10.1134/S1607672919010150
V. Koundal, Q. Mohd, R. Haq, and S. Praveen, Biochem. Genet. 49, 25 (2011). https://doi.org/10.1007/S10528-010-9382-8
J. A. Chichester, R. M. Jones, B. J. Green, et al., Viruses 4, 3227 (2012). https://doi.org/10.3390/v4113227
W. Phoolcharoen, Q. Dye, J. Kilbourne, et al., Proc. Natl. Acad. Sci. U. S. A. 108, 20695 (2011). https://doi.org/10.1073/pnas.1117715108/-/DCSupplemental
S. Marillonnet, A. Giritch, M. Gils, et al., Proc. Natl. Acad. Sci. U. S. A. 101, 6852 (2004). https://doi.org/10.1073/pnas.0400149101
R. K. Salyaev, N. I. Rekoslavskaya, A. S. Stolbikov, and A. V. Tretyakova, Dokl. Biochem. Biophys. 468, 187 (2016). https://doi.org/10.1134/S1607672916030078
C. Foresta, C. Patassini, A. Bertoldo, et al., PLoS One 6, e15036 (2011). https://doi.org/10.1371/journal.pone.0015036
M. Dreer, J. Fertey, S. van de Poel, et al., PLOS Pathogens 12, e1005556 (2016). https://doi.org/10.1371/journal.ppat.1005556
N. Wong, P. Major, A. Kapoor, et al., Oncotarget 7, 83115 (2016).
R. Rosales, M. Lopez-Countreras, C. Rosales, et al., Human Gene Ther. 25, 1035 (2014). https://doi.org/10.1089/hum.2014.024
Conflict of interests. The authors declare that they have no conflict of interest.
Statement on the welfare of animals. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Translated by M. Novikova
About this article
Cite this article
Salyaev, R.K., Rekoslavskaya, N.I. & Stolbikov, A.S. New Data on the Influence of the HPV16 E2 Early Protein Obtained in Plant Expression Nanosystems on Tumor Tissues of Female Mice Induced by Injection of HeLa Cancer Cells in Hip Muscle. Nanotechnol Russia 15, 516–522 (2020). https://doi.org/10.1134/S1995078020040138